. "0015-5500" . . "P(GA301/00/0564), P(NC7139), Z(MZ00020980501)" . "Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients"@en . "CZ - \u010Cesk\u00E1 republika" . "4"^^ . . . . "Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients" . "4"^^ . . . "Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients"@en . "610906" . "Kova\u0159\u00EDk, Jan" . "Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients" . . . . "Using immunoprecipitation and Western blots performed on lysates made of melanoma cells derived from patients with clinical stage II/III and employing specific anti-STAT 1 PS 727/PY 701 immunoprobes, we show that STAT 1 activation response induced by IFN-alfa/-gamma is significantly impaired. In average, three quarters of patients were lacking phosphorylation at S 727. STAT 1 PY 701 was not inducible by IFN-alfa in 63% and by IFN-gamma in 34% of samples However, these STAT 1 activation defects showed no correlation with the disease outcome and immunotherapy response as indicated by progression-free survival profiles in patients treated with IFN-alfa2b."@en . . "142; 146" . "5"^^ . . "Folia Biologica" . "RIV/00209805:_____/03:00008209!RIV/2004/GA0/L26004/N" . "[9C1073143088]" . "4" . "STAT 1;malignant melanoma;signal transduction;interferons"@en . . "RIV/00209805:_____/03:00008209" . . "49" . . "Using immunoprecipitation and Western blots performed on lysates made of melanoma cells derived from patients with clinical stage II/III and employing specific anti-STAT 1 PS 727/PY 701 immunoprobes, we show that STAT 1 activation response induced by IFN-alfa/-gamma is significantly impaired. In average, three quarters of patients were lacking phosphorylation at S 727. STAT 1 PY 701 was not inducible by IFN-alfa in 63% and by IFN-gamma in 34% of samples However, these STAT 1 activation defects showed no correlation with the disease outcome and immunotherapy response as indicated by progression-free survival profiles in patients treated with IFN-alfa2b." . . . . . "Boudn\u00FD, Vladim\u00EDr" . .